Cantor Fitzgerald Reaffirms Overweight Rating for ADMA Biologics (NASDAQ:ADMA)

Cantor Fitzgerald reissued their overweight rating on shares of ADMA Biologics (NASDAQ:ADMA - Free Report) in a research report sent to investors on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $25.00 price objective on the biotechnology company's stock.

A number of other equities research analysts have also recently weighed in on ADMA. HC Wainwright increased their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research report on Friday, November 8th.

ADMA Biologics Stock Performance

NASDAQ ADMA traded down $0.13 during trading on Tuesday, reaching $17.55. 825,161 shares of the company's stock were exchanged, compared to its average volume of 3,351,924. ADMA Biologics has a fifty-two week low of $5.71 and a fifty-two week high of $23.64. The stock has a market capitalization of $4.15 billion, a P/E ratio of 62.67 and a beta of 0.75. The business has a 50 day moving average price of $16.69 and a 200-day moving average price of $17.97. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hollencrest Capital Management bought a new stake in shares of ADMA Biologics in the third quarter valued at about $30,000. Larson Financial Group LLC acquired a new stake in ADMA Biologics in the 3rd quarter worth about $31,000. National Bank of Canada FI bought a new stake in ADMA Biologics in the 3rd quarter valued at about $35,000. GAMMA Investing LLC boosted its holdings in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 967 shares during the period. Finally, Mark Sheptoff Financial Planning LLC acquired a new position in shares of ADMA Biologics during the 4th quarter worth approximately $35,000. 75.68% of the stock is owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.